Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 10/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 10/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 10/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 10/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.34 |
| ▸ | TYR | P14679 | 1/20 | 0.33 |
| ▸ | PDE1A | P54750 | 2/20 | 0.33 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.33 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19195306 | 1.00 | PDE4A (0.36) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL19195169 | 0.86 | NFE2L2 (0.33) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL19195307 | 0.86 | NFE2L2 (0.33) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL19196409 | 0.82 | NFE2L2 (0.32) | NFE2L2 | |
| SCHEMBL19195552 | 0.82 | NFE2L2 (0.32) | NFE2L2 | |
| SCHEMBL19195310 | 0.81 | NFE2L2 (0.37) | NFE2L2 | |
| SCHEMBL19196410 | 0.81 | NFE2L2 (0.37) | NFE2L2 | |
| SCHEMBL19195560 | 0.80 | NFE2L2 (0.33) | NFE2L2 | |
| SCHEMBL19195309 | 0.80 | NFE2L2 (0.33) | NFE2L2 | |
| SCHEMBL19195396 | 0.78 | ADORA2B (0.31) | ADORA2BNFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9845307-B2 | Nrf2 activating compounds and uses thereof | MIDCAP FINANCIAL TRUST | 2017-12-19 | — | — | US | disclosed |
| US-20170217922-A1 | Nrf2 Activating Compounds and Uses Thereof | MIDCAP FINANCIAL TRUST | 2017-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217922-A1 | Nrf2 Activating Compounds and Uses Thereof | NFE2L2, KEAP1, NQO1 | PDE4A 984/4885PDE4B 1160/4885PDE4C 1262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.